JP2015529802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529802A5 JP2015529802A5 JP2015521863A JP2015521863A JP2015529802A5 JP 2015529802 A5 JP2015529802 A5 JP 2015529802A5 JP 2015521863 A JP2015521863 A JP 2015521863A JP 2015521863 A JP2015521863 A JP 2015521863A JP 2015529802 A5 JP2015529802 A5 JP 2015529802A5
- Authority
- JP
- Japan
- Prior art keywords
- nachr
- flna
- amount
- hydrocarbyl
- tlr4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 claims description 53
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 claims description 53
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 32
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000007792 alzheimer disease pathology Effects 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 238000000034 method Methods 0.000 claims 41
- 102000004169 proteins and genes Human genes 0.000 claims 39
- 108090000623 proteins and genes Proteins 0.000 claims 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 25
- 229910052757 nitrogen Inorganic materials 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 12
- 102000005962 receptors Human genes 0.000 claims 12
- 108020003175 receptors Proteins 0.000 claims 12
- 239000001301 oxygen Substances 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 9
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 9
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 239000011593 sulfur Substances 0.000 claims 9
- -1 C-1 compound Chemical class 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 7
- 238000005259 measurement Methods 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical group CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 2
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 102000013366 Filamin Human genes 0.000 claims 2
- 108060002900 Filamin Proteins 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000002764 solid phase assay Methods 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- SEJUQQOPVAUETF-QHLBDZCJSA-N (2r,6r,11s)-3-(cyclopropylmethyl)-6-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2h)-one Chemical compound C([C@@]1([C@@H]([C@@H]2C(=O)C=3C1=CC(O)=CC=3)C)CC)CN2CC1CC1 SEJUQQOPVAUETF-QHLBDZCJSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229950002494 diprenorphine Drugs 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- AKXCFAYOTIEFOH-XTNAHFASSA-N n-[(e)-[(4r,4as,7ar,12bs)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ylidene]amino]benzamide Chemical compound C1(/[C@H]2[C@]34CCN(CC=C)[C@@H]([C@@]4(CC1)O)CC1=CC=C(C(O2)=C13)O)=N\NC(=O)C1=CC=CC=C1 AKXCFAYOTIEFOH-XTNAHFASSA-N 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 1
- 229960000938 nalorphine Drugs 0.000 claims 1
- AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 claims 1
- 102100026561 Filamin-A Human genes 0.000 description 4
- 101000913549 Homo sapiens Filamin-A Proteins 0.000 description 4
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671445P | 2012-07-13 | 2012-07-13 | |
| US61/671,445 | 2012-07-13 | ||
| US201361789180P | 2013-03-15 | 2013-03-15 | |
| US61/789,180 | 2013-03-15 | ||
| PCT/US2013/050368 WO2014012054A1 (en) | 2012-07-13 | 2013-07-12 | Alzheimer's disease assay in a living patent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019139317A Division JP6796168B2 (ja) | 2012-07-13 | 2019-07-30 | 生きている患者でのアルツハイマー病アッセイ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015529802A JP2015529802A (ja) | 2015-10-08 |
| JP2015529802A5 true JP2015529802A5 (enExample) | 2016-09-01 |
| JP6566867B2 JP6566867B2 (ja) | 2019-08-28 |
Family
ID=49914282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015521863A Active JP6566867B2 (ja) | 2012-07-13 | 2013-07-12 | 生きている患者でのアルツハイマー病アッセイ |
| JP2019139317A Active JP6796168B2 (ja) | 2012-07-13 | 2019-07-30 | 生きている患者でのアルツハイマー病アッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019139317A Active JP6796168B2 (ja) | 2012-07-13 | 2019-07-30 | 生きている患者でのアルツハイマー病アッセイ |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US9354223B2 (enExample) |
| EP (1) | EP2872899B1 (enExample) |
| JP (2) | JP6566867B2 (enExample) |
| WO (1) | WO2014012054A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2872899B1 (en) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
| WO2014100730A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| US9221794B2 (en) | 2012-12-21 | 2015-12-29 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| EP3498701B1 (en) | 2012-12-21 | 2023-02-22 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| EP3177288A4 (en) | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP6463162B2 (ja) * | 2015-02-10 | 2019-01-30 | キヤノン株式会社 | 記録制御装置、記録制御方法、及びプログラム |
| PL3313755T3 (pl) * | 2015-06-26 | 2020-01-31 | Bisio Progetti S.P.A. | Kapsułka jednodawkowa do sporządzania napojów |
| PE20180694A1 (es) | 2015-07-31 | 2018-04-23 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il-carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il-carbamato como inhibidores de magl |
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| KR20190096949A (ko) | 2016-10-05 | 2019-08-20 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 소분자 ampk 활성화제 |
| WO2018134695A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors |
| CN110198944A (zh) | 2017-01-23 | 2019-09-03 | 辉瑞大药厂 | 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物 |
| CA3079819C (en) * | 2017-11-06 | 2023-03-14 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation |
| US12186307B2 (en) | 2019-02-13 | 2025-01-07 | Yale University | Methods of treating epilepsy |
| CN114072406B (zh) | 2019-02-21 | 2025-03-18 | 卡萨瓦科学公司 | Flna-结合化合物及其盐酸盐的固体多晶型物 |
| EP3934647A1 (en) * | 2019-03-06 | 2022-01-12 | LDN Pharma Limited | Method for determining efficacy |
| US12428378B2 (en) | 2019-09-10 | 2025-09-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and materials for increasing level of phosphorylated AMPK protein |
| AU2021376267A1 (en) * | 2020-11-03 | 2023-06-15 | Cassava Sciences, Inc. | Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4 |
| CN118043671A (zh) * | 2021-07-23 | 2024-05-14 | 卡萨瓦科学公司 | 用于活体受试者中阿尔茨海默病的组分测定 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1220440B (de) | 1962-02-14 | 1966-07-07 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| PT1007033E (pt) * | 1997-08-28 | 2008-07-22 | Novartis Ag | Antagonistas do antigénio-1 da função de linfócitos |
| DK1083889T3 (da) * | 1998-06-01 | 2004-04-13 | Ortho Mcneil Pharm Inc | Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme |
| AU1920401A (en) * | 1999-12-01 | 2001-06-12 | Ortho-Mcneil Pharmaceutical, Inc. | Method of diagnosing neurodegenerative disease |
| DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| AU2003223098A1 (en) | 2002-01-14 | 2003-09-02 | Sun Pharmaceutical Industries Limited | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone |
| KR101027570B1 (ko) | 2002-05-03 | 2011-04-06 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물 |
| US20070149543A1 (en) | 2003-01-29 | 2007-06-28 | Stockwell Brent R | Agents For Treating Neurodegenerative Diseases |
| DE102004014304A1 (de) * | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen |
| DE102004014296A1 (de) | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| US20090170957A1 (en) | 2005-10-13 | 2009-07-02 | Antonio Cruz | Scyllo-inositol derivatives and their use in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| FR2905009A1 (fr) * | 2006-08-18 | 2008-02-22 | Servier Lab | Methode de criblage de composes aux proprietes anti-amyloide |
| US8722851B2 (en) | 2007-11-02 | 2014-05-13 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A |
| US8653068B2 (en) | 2009-10-30 | 2014-02-18 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| US8614324B2 (en) | 2008-10-31 | 2013-12-24 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US8580808B2 (en) | 2009-10-30 | 2013-11-12 | Pain Therapeutic, Inc. | Filamin A-binding anti-inflammatory analgesic |
| US20100279997A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Analgesic that binds filamin a |
| US20100279996A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| CA2750928A1 (en) | 2009-01-28 | 2010-08-05 | Catholic Healthcare West | Methods of diagnosing and treating neurodegenerative diseases |
| US20100280061A1 (en) | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
| US8580809B2 (en) | 2009-10-30 | 2013-11-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
| EP2872899B1 (en) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
| DK2882428T3 (en) * | 2012-07-13 | 2019-04-15 | Pain Therapeutics Inc | PROCEDURE TO INHIBIT TAU PHOSPHORIZATION |
-
2013
- 2013-07-12 EP EP13816628.5A patent/EP2872899B1/en active Active
- 2013-07-12 JP JP2015521863A patent/JP6566867B2/ja active Active
- 2013-07-12 WO PCT/US2013/050368 patent/WO2014012054A1/en not_active Ceased
- 2013-07-15 US US13/942,326 patent/US9354223B2/en active Active
- 2013-07-18 US US13/945,612 patent/US9500640B2/en active Active
-
2016
- 2016-05-27 US US15/167,370 patent/US10222368B2/en active Active
-
2019
- 2019-02-28 US US16/289,215 patent/US11385221B2/en active Active
- 2019-07-30 JP JP2019139317A patent/JP6796168B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529802A5 (enExample) | ||
| AU2014348523B2 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| BR112021005606A2 (pt) | processo de produção de um composto para inibir a atividade de shp2 | |
| JP2019218375A5 (enExample) | ||
| CN110494423B (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
| JP2019533670A5 (enExample) | ||
| JP5600122B2 (ja) | （２ｓ，３ｒ）−ｎ−２−（（３−ピリジニル）メチル）−１−アザビシクロ［２．２．２］オクタ−３−イル）−３，５−ジフルオロベンズアミドの調製及び治療への適用 | |
| US20110312961A1 (en) | 2,5-Disubstituted Morpholine Orexin REceptor Antagonists | |
| CN110785417A (zh) | 膜铁转运蛋白抑制剂盐 | |
| EA020024B1 (ru) | Новые кристаллические формы и способ получения 5-({[2-амино-3-(4-карбамоил-2,6-диметилфенил)пропионил]-[1-(4-фенил-1н-имидазол-2-ил)этил]амино}метил)-2-метоксибензоевой кислоты | |
| JP2015523385A5 (enExample) | ||
| CN108472242A (zh) | 治疗癌症的药物组合 | |
| IL302913A (en) | FGFR inhibitors and methods for their preparation and use | |
| KR102424621B1 (ko) | 로라티닙 유리 염기 수화물의 결정질 형태 | |
| JPH02117684A (ja) | フラン誘導体 | |
| EP4247472A1 (en) | Integrin inhibitor and uses thereof | |
| KR20120081166A (ko) | 매크로시클릭 그렐린 수용체 효능제의 염, 용매화물 및 약제학적 조성물 및 이를 사용하는 방법 | |
| JP2018531987A5 (enExample) | ||
| KR20210099066A (ko) | 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체 | |
| JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
| WO2022258584A1 (en) | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide | |
| Wang et al. | Discovery and identification of Cdc37-derived peptides targeting the Hsp90–Cdc37 protein–protein interaction | |
| AU2020221247B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| TW201335161A (zh) | 二氫吡咯并［１，２－ｃ］咪唑基皮質醛酮素合成酶或芳族酶抑制劑之新穎型式及鹽 | |
| TWI727314B (zh) | 盛格列汀的鹽、其製備方法與用途以及藥物組合物 |